

Eisai breaks ground for global drug discovery centre

16 December 2019 | News

For connecting human and human, and data, and the world



Japan based Eisai Co., Ltd. has had a groundbreaking ceremony for a major renovation of its Tsukuba Research Laboratories (Ibaraki, Japan) as part of strategic investment to realize Eisai's medium-term business plan "EWAY2025."

Since the opening in 1982, the Tsukuba Research Laboratories has led the creation of innovation by discovering the cutting-edge drugs including Aricept[®], Pariet[®], Lenvima[®] and Fycompa[®] over the last approximate 40 years.

In order for the Tsukuba Research laboratories to continue to play the central role also in the next generation innovation creation as Eisai's global drug discovery center, a major renovation is conducted with a key concept "Human Connected Laboratories : Laboratories Connecting Human and Human, and Data, and the World." This renovation aims to accelerate the further knowledge circulation by connecting each researcher with patients, other members at the Tsukuba Research Laboratories, the research sites in the world, and external researchers, as well as developing the environment for the further digitalization era.

In order to accelerate the knowledge exchange in the Tsukuba Research Laboratories and to support the workstyle to increase the researchers' efficiency, the renovation for improving the traffic lines between workspaces or research buildings, as well as building the spaces for various co-creation are conducted.

The Tsukuba Research Laboratories is a core research center for drug discovery research in the neurology and oncology fields, which are our priority areas, and conducts the drug discovery activities with the aim of contributing to global health including neglected tropical diseases. In addition, the Tsukuba Research Laboratories will also play a central role as a base for Data Driven Drug Discovery & Development (5D drug discovery) to create a paradigm shift in drug discovery by digital technology. Through these initiatives, Eisai accelerates the drug discovery activities, and is striving to further contribute to satisfy unmet medical needs and to improve the benefits to patients and their families.